Clinical trials: Living Donor of Kidney
Kidney Transplant Rejection
Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants
The primary objective of this study is to demonstrate the safety and efficacy of cellular immunotherapy with MDR-101 for induction of functional immune tolerance in recipients of human leukocyte antigen (HLA)-matched, living…
- Trial name
- NCT03363945
- Testing
- MDR-101
- Where
- 19 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Medeor Therapeutics, Inc.
Kidney Transplantation
REgulatory T Cell Therapy to Achieve Immunosuppression REduction
The goal of this multi-national, multi-center, open-label, randomized Phase 2 trial is to determine the safety and efficacy of administering expanded regulatory T cells (TRK-001) to prevent allograft rejection in living donor…
- Trial name
- RETIRE (NCT06552169)
- Testing
- Arm 1: SOC (mTOR + CNI), Arm 2A: TRACT/MONO mTOR, Arm 2B: TRACT/MONO CNI
- Where
- 7 sites in United States, Taiwan
- Volunteers
- 34 people
- Sponsor
- Singulera Therapeutics Inc.
Kidney Transplantation, Acute Graft Rejection
Pre-formed Alloreactivity in Renal Transplant Recipients
This investigator-initiated study will analyse the role of pre-formed alloreactive T cells on acute rejection episodes and graft outcome in kidney transplant recipients after living donation.
- Trial name
- NCT02633826
- Where
- 13 sites in Germany
- Volunteers
- 190 people
- Sponsor
- Martina Sester
End-stage Renal Disease
Implementation of the Live Donor Champion Program
The Live Donor Champion Program is a clinical education program offered to patients placed on the waitlist for kidney transplantation at the Johns Hopkins Comprehensive Transplant Center.
- Trial name
- LDC (NCT03435510)
- Testing
- Live Donor Champion Program
- Where
- 2 sites in United States
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Function of Renal Transplant
RituxiMab INDuction in Renal Transplantation
Hypothesis: That B cell depletion, rather than reducing acute rejection, will allow minimisation of immunosuppression, which may lead to better graft survival.
- Trial name
- ReMIND (NCT01095172)
- Testing
- Rituximab, Tacrolimus, Mycophenylate mofetil
- Where
- 6 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Kidney Transplant Rejection
Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney Transplantation
Kidney transplantation is the best available treatment option for patients with end stage renal disease. However, kidney transplantation requires life-long use of immunosuppressive medication.
- Trial name
- NCT03789006
- Testing
- Antithymocyte Immunoglobulin (Rabbit), Interleukin 2 Receptor Antagonist
- Where
- Sudan
- Volunteers
- 300 people
- Sponsor
- University of Khartoum
Kidney Transplantation, Living Donors
Randomized Trial of Cyclosporine and Tacrolimus Therapy With Steroid Withdrawal in Living-Donor Renal Transplantation
The use of steroids after kidney transplantation has been challenged because of variable adverse effects which may increase the patient morbidity and mortality.
- Trial name
- NCT00777933
- Testing
- tacrolimus, cyclosporine
- Where
- South Korea
- Volunteers
- 131 people
- Sponsor
- Samsung Medical Center
Renal Transplant Rejection, Transplants and Implants
Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients
To determine how safe and effective giving Thymoglobulin before transplantation to patients who are going to be receiving kidney transplants.
- Trial name
- NCT00771745
- Testing
- Thymoglobulin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Cincinnati
Chronic Kidney Diseases
LONGitudinal Multi-omics Phenotyping of KIDney Function Alteration
This is a longitudinal observation of kidney function, immune system and gut microbiota before and 24 weeks after a live kidney transplantation conducted in donor and recipient pairs living in the same household.
- Trial name
- NCT05570929
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Kidney Diseases, Transplant Failure
Evaluation of APOL1 Gene Variants in Kidney Donors and Their Impact on Long-term Renal Function in Donors and Recipients
Evaluation of the frequency of APOL1 gene variants in kidney donors and the impact of these variants on the long-term renal function of kidney transplant donors and recipients.
- Trial name
- NCT06116721
- Where
- Brazil
- Volunteers
- 2,450 people
- Sponsor
- Hospital do Rim e Hipertensão
Kidney Transplantation
Abnormalities of Preoperative Ascending Urethrocystography and Outcomes of Living Donor Kidney Transplantation
To evaluate effects of abnormalities in preoperative ascending urethrocystography on the short-term outcomes of LDKT
- Trial name
- NCT06735066
- Testing
- Ascending urethrocystography
- Volunteers
- 80 people
- Sponsor
- Assiut University
Renal Transplant
Belatacept to Prevent Organ Rejection in Kidney Transplant Patients
Belatacept is an experimental medication shown in clinical trials to have immune system suppression properties in people who have had renal (e.g., kidney) transplants.
- Trial name
- BESTT (NCT00346151)
- Testing
- Belatacept, Sirolimus, Anti-thymocyte globulin
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplantation
Certican (Everolimus) for Recipients of Kidney From HLA-identical Living Donors
Recipients from living donors kidneys HLA-identical were lower risk for acute rejection, graft loss or death. There is no clear definition of what is ideal immunosuppressive regimen for this population.
- Trial name
- NCT01653041
- Testing
- Everolimus
- Where
- Brazil
- Volunteers
- 47 people
- Sponsor
- Hospital do Rim e Hipertensão
Kidney Transplant Failure and Rejection, Gender
Sex Impact on Long-term Outcomes of LDKT
The impact of donor and recipient gender combination on kidney transplant outcomes has been reported in several studies. The results vary greatly due to different factors, such as minor histocompatibility antigens, nephron…
- Trial name
- NCT06016283
- Where
- Netherlands
- Volunteers
- 1,276 people
- Sponsor
- Erasmus Medical Center
ABO Blood Type Incompatible Kidney Transplantation
Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) as Conditioning Regimen for ABO-incompatible Living Donor Kidney Transplantation
The goal of this clinical trial was to determine whether the Bites drugs (Blinatumomab and Teclistamab) can reduce blood group antibodies in recipients of living donor blood-incompatible kidney transplants for pretransplant…
- Trial name
- NCT07706205
- Testing
- Blinatumomab Treatment, Teclistamab treat
- Volunteers
- 20 people
- Sponsor
- West China Hospital
Cytomegalovirus Infections
Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients
Cytomegalovirus (CMV) infection remains one of the most frequent infectious complications after kidney transplantation. In intermediate-risk recipients (seropositive, R+ recipient) of living donor kidney transplants, optimal…
- Trial name
- (PREVAIL-KT) (NCT07430683)
- Testing
- Valganciclovir Prophylaxis, Preemptive Therapy (CMV PCR Monitoring)
- Where
- Mexico
- Volunteers
- 68 people
- Sponsor
- University of Guadalajara
Kidney Stones, Urolithiasis, Hypocitraturia, Living Kidney Donation
Long-Term Risk of Kidney Stones in Living Kidney Donors
Using a population-based, matched, retrospective cohort approach, this study will evaluate the long-term risk of kidney stones among living kidney donors compared with matched healthy nondonors.
- Conditions
- Kidney Stones, Urolithiasis, Hypocitraturia, Living Kidney Donation, Living Kidney Donor
- Trial name
- NCT07611500
- Testing
- Living kidney donation
- Volunteers
- 50,000 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Living Donor Kidney Transplantation
TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation
This study will determine whether a preparatory regimen including total lymphoid irradiation (TLI), total body irradiation (TBI), anti-thymocyte globulin (ATG) and infusion of the donor hematopoietic stem cells when given along…
- Trial name
- NCT03943238
- Testing
- Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Stanford University
Kidney Diseases
Comparative Renal Function of Young (18-45 Years) and Ageing (55 Years and Above) Kidney Donors
It is our purpose in this study to compare the kidney structure and function of older patients to that of young patients before and after removal of a single kidney for transplant donation and to examine the remaining kidney's…
- Trial name
- NCT00846729
- Testing
- CT angiogram of the remaining kidney., Kidney Function study using Iothalamate & PAH as clearance markers
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Stanford University
Living Donor Kidney Transplants Patients
Comparison of Tacrolimus and Myfortic Versus Tacrolimus and Sirolimus
The investigators center has also analyzed data over the last 7 years from deceased donor (DD) and living donor (LD) kidney transplant recipients who were randomized into 3 immunosuppressive arms between 2000 and 2001.
- Trial name
- NCT01038505
- Testing
- Tacrolimus, Myfortic and Sirolimus
- Sponsor
- University of Miami